Recent Articles

• Amylin, Lilly, and Alkermes Await FDA Decision on Byetta for Diabetes
• BioHorizon Health Technology Surveillance Update: February 8, 2010
• Oral Therapies for Multiple Sclerosis – Fingolimod (FTY 720) and Cladribine: How Close are Novartis and Merck KGaA to FDA Approval?
• Making Sense of Clinical Trials: A Guide for BioHorizon Clients
• MannKind’s AFREZZA vs. Pfizer’s Exubera: Will Inhaled Insulin Be Different This Time?
• ADVENTRX Pharmaceuticals, Inc. and the 505(b)(2) New Drug Application (NDA) for ANX-530
• Pneumococcal Disease In Children
• Wyeth vs. GSK: A Vaccine Showdown?
• OSI Pharmaceuticals and Genentech’s Tarceva Non-Small Cell Lung Cancer Therapy
• Nabi Biopharmaceuticals Altastaph for the Prevention and Treatment of Staph. Aureus Infections
• Abbott Labs ABT-874 for Treatment of Crohn’s Disease
• Nitromed’s BiDil Combination Therapy for Congestive Heart Failure
• Sanofi-Synthelabo’s Eloxatin for Postsurgical Treatment of Stage III Colon Cancer
• MedImmune’s CAIV-T Influenza Vaccine
• DePuy Spine’s Charite Artificial Disc for Replacement of Spinal Discs